Lim, Ee Lyn <br/><br/>
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.  [electronic resource] 

 -  JCI insight  06 2018 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2379-3708 
<br/><br/><label>Standard No.: </label>10.1172/jci.insight.120626  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antigens, Neoplasm--administration & dosage<br/>Antineoplastic Agents, Immunological--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cancer Vaccines--pharmacology<br/>Cell Line, Tumor--transplantation<br/>Class I Phosphatidylinositol 3-Kinases<br/>Costimulatory and Inhibitory T-Cell Receptors--antagonists & inhibitors<br/>Diphtheria Toxin--administration & dosage<br/>Disease Models, Animal<br/>Drug Interactions<br/>Female<br/>Humans<br/>Lymphocyte Depletion--methods<br/>Male<br/>Mice<br/>Neoplasms--drug therapy<br/>Phosphatidylinositol 3-Kinases--immunology<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Purines--pharmacology<br/>Quinazolinones--pharmacology<br/>Signal Transduction--drug effects<br/>T-Lymphocytes, Cytotoxic--drug effects<br/>T-Lymphocytes, Regulatory--drug effects<br/>Treatment Outcome